



## **Adicet Bio to Participate in a Fireside Chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference**

March 11, 2024

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Mar. 11, 2024-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference being held March 26, 2024.

Details of the event are as follows:

Date: Tuesday, March 26, 2024

Time: 10:30 a.m. ET

The live audio webcast of the presentation can be accessed on the Investors section of Adicet Bio's website at <http://www.adicetbio.com>. An archived replay will be available for 30 days following the presentation.

### **About Adicet Bio, Inc.**

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. Adicet is advancing a pipeline of "off-the-shelf" gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. For more information, please visit our website at <https://www.adicetbio.com>.

View source version on [businesswire.com](https://www.businesswire.com): <https://www.businesswire.com/news/home/20240311201028/en/>

### **Adicet Bio., Inc.**

#### **Investor and Media Contacts**

Anne Bowdidge

[abowdidge@adicetbio.com](mailto:abowdidge@adicetbio.com)

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

[janhavi.mohite@sternir.com](mailto:janhavi.mohite@sternir.com)

Source: Adicet Bio, Inc.